Objective: This study aimed to describe the relative and excess risk of pancreatic neuroendocrine tumor (NET) at least 6 months after the first primary cancer (FPC) among the US population.
P
ancreatic cancer is the 11th most commonly diagnosed cancer and the 4th leading cause of cancer-related death in the United States. 1 An estimated 12.6 new cases are diagnosed per 100,000 persons, and 10.9 per 100,000 persons die of it every year. 2 Overall, the case fatality rate is high, with only 8.5% of pancreatic cancer patients living 5 years past diagnosis. Five-year survival is better for tumors diagnosed at the localized stage at 34.3%; however, these constitute only 10% of cases. Most cases (52%) are diagnosed at the distant stage, for which the survival rate is an abysmal 2.7%. 2 Although less than 5% of all pancreatic cancers are neuroendocrine, the pancreas is one of the most common sites for neuroendocrine tumors (NETs). 3, 4 Pancreatic NETs histologically resemble carcinoid gastrointestinal tract tumors, but respond differently to treatment, and are therefore recognized as a separate entity. 3 They can be classified as functional (hormone-producing) and nonfunctional. Nonfunctional pancreatic NETs, making up approximately 15% to 53% of pancreatic NET, may initially be asymptomatic and therefore detected at a late clinical stage. By the time of diagnosis, the tumor has often enlarged and/or metastasized. 5, 6 Hence, identifying persons at highest risk for this cancer is crucial in reducing the fatality rate via screening, early detection, and treatment.
Most cases of pancreatic NET are sporadic; however, some occur as part of the autosomal dominant multiple endocrine neoplasia type 1 (MEN1) inherited syndrome, which includes neoplasia in the anterior pituitary, parathyroid, and endocrine pancreas. 3 Risk factors for sporadic pancreatic NET include cigarette smoking, heavy alcohol drinking, and a history of diabetes and of cancer in a first-degree family member, 7 similar to risk factors for NETs at any site. 8 A case/control study found that pancreatic NET patients were more likely than controls to report a family member with pancreatic NET, sarcoma, and gallbladder, ovarian, and gastric cancer. 9 However, it is not known whether a history of cancer is associated with increased risk of pancreatic NET in the same individual.
Therefore, we conducted a study based on US population data with the following objectives: (1) to assess whether the risk of developing a primary pancreatic NET is increased in persons who previously had a primary cancer diagnosis compared with the general population, (2) to assess whether a history of a first primary cancer (FPC) at specific sites increases the risk of developing a second primary pancreatic NET, and (3) to describe the excess risk of developing a second primary pancreatic NET among those who previously had a primary cancer diagnosis at specific sites compared with the general population.
MATERIALS AND METHODS
Data were extracted from the Surveillance, Epidemiology, and End-Results (SEER) Program's November 2017 release of the SEER 18 registry. 10 Geographic areas covered include Greater California, Greater Georgia, Kentucky, Louisiana, and New Jersey in addition to the SEER 9 (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah) and the SEER 13 areas (Los Angeles, San JoseMonterey, Rural Georgia, and the Alaska Native Tumor Registry).
Inclusion criteria were defined as patients who had a first cancer diagnosis of a primary malignant cancer from 2000 to 2015. Postmortem cases and nonmicroscopically confirmed cases were excluded. Secondary analyses were also conducted on a subcohort of patients, defined as those diagnosed as having a primary malignant cancer of neuroendocrine histology. Neuroendocrine tumors were defined by cancers with the following ICD-O3 histology/ behavior codes: 8150/3-8157/3, 8240/3-8250/3, and 9190/3.
The outcome was the occurrence of a second primary pancreatic NET, defined by an intersection of the SEER variable Site recode B ICD-O3/WHO 2008 = "Pancreas" and the herein reported NET histology codes, at least 6 months after diagnosis of the FPC; this latency period was used to decrease the likelihood of the pancreatic NET being a preexisting tumor or incidental finding. The SEER Program uses a definition of multiple primaries that is outlined in the SEER coding manual, which takes account of histology, site, laterality, and time since initial diagnosis to identify multiple primary cancers. 11 
Statistical Analysis
A single-outcome analysis was used, so that patients contributed person-time to the study starting 6 months after their FPC diagnosis and exited the study (ie, stopped contributing person-time) at the earliest of the following events: a diagnosis of pancreatic NET, death, or loss to follow-up.
The distribution of demographic (age group, sex, race/ ethnicity, marital status) and tumor characteristics (year of diagnosis, stage, histologic type, second primary tumor) among the overall and the NET cohort was obtained using a frequency session in SEER*Stat. Next, the multiple primary-standardized incidence ratio session of the SEER*Stat program was used to calculate age-adjusted standardized incidence ratios (SIRs), 95% confidence intervals (CIs), and excess risk among the overall and the NET cohort. The SIRs represent the relative risk of developing a pancreatic NET among patients who had an FPC compared with the general population, according to the sex and anatomical site of FPC as follows: SIR = observed number of pancreatic NET cases at a particular tumor site/expected number of pancreatic NET cases at that particular tumor site. 12 The expected number of pancreatic NET cases was calculated by multiplying age-and sex-specific population cancer incidence rates with the age-and sex-specific person-years at risk among the cohort, using the formula: (observed number of pancreatic NET cases in the population/population's person-years at risk) Â FPC patients' person-years at risk. The excess risk of second primary pancreatic NET per 10,000 persons per year for each FPC site was calculated as follows: ((observed number of pancreatic NET among FPC patients − expected number of pancreatic NET cases) Â 10,000)/FPC patients' person years at risk. The average time to diagnosis of second primary pancreatic NETwas calculated in months using the mean person-years at risk for each primary cancer site.
Statistical analyses were conducted using SEER*Stat software (National Cancer Institute, DCCPS, Surveillance Research Program SEER*Stat software [www.seer.cancer.gov/seerstat] version 8.3.4).
RESULTS
In 2000 to 2015, 4,008,092 persons were reported in SEER with a diagnosis of a primary malignant cancer, of which 67,414 (1.7%) had neuroendocrine histology (Table 1) . Most patients was aged 45+ years and white; the NET cohort had a slightly higher proportion of blacks (13.2%) compared with the overall cohort (10.6%). The overall cohort had a balanced sex distribution, but a slight majority (54%) of the NET cohort was female.
A slightly higher proportion of NETs were diagnosed at the distant stage (17.6%) compared with the overall cohort (15.1%). Similar proportions of both cohorts were diagnosed as having a second primary cancer; however, a much higher proportion of the second primary tumors in the NET cohort were of neuroendocrine histology (14.7%) compared with just 2.3% in the overall cohort.
Persons diagnosed as having an FPC at any site and for any solid tumor had a significantly higher risk of developing a second primary pancreatic NET compared with the general population (SIR, 1.3; 95% CI, 1.2-1.5). Site-specific results show a significantly higher risk of developing a second primary pancreatic NET after a primary cancer of the pancreas, thymus, adrenal gland, and other endocrine organs; small intestine, liver, and biliary organs; stomach, esophagus, and other digestive organs; kidney, renal pelvis and other urinary organs; lung and other respiratory organs; female breast; and miscellaneous organs ( Table 2 ). In the "miscellaneous" site group, the increased risk was due to cancers in the soft tissue including heart cancer In the NET group, the relative risk of a second primary pancreatic NET was even higher after any NET primary (SIR, 8.0; 95% CI, 5.8-10.6) and after any solid NET (SIR, 8.2; 95% CI, 5.9-11.1). The risk of a second primary pancreatic NET was significantly increased after a primary in the same organs as in the general cohort, except for liver and biliary organs (1 case), and kidney, renal pelvis, and other urinary organs (0 cases) ( Table 2 ). In the miscellaneous site group, the increased risk was solely due to a primary nonmelanoma, nonepithelial skin cancer (SIR, 8.4; 95% CI, 1.7-24.5). In addition, having a primary cancer of the urinary bladder significantly increased the risk of a second primary pancreatic NET. The excess risk of having a second primary pancreatic NET among those with a primary NET at any site was 1.3 per 10,000 person-years and was highest for those with a primary cancer in the urinary bladder (27.1 cases/10,000 personyears), followed by the thymus (12.3 cases/10,000 person-years), female breast (11.8 cases per 10,000 person-years), and pancreas (6.9 cases per 10,000 person-years).
When data are stratified according to sex (Table 3) , among men, the risk of developing a second primary pancreatic NET was significantly increased after any primary cancer and any solid tumor, as well as primary cancer in the pancreas, thymus, adrenal gland, and other endocrine organs; small intestine, liver, and biliary organs; kidney, renal pelvis, and other urinary organs; and lung and other respiratory organs. Risk was also significantly Among women, the risk of developing a second primary pancreatic NETwas significantly increased after a primary cancer of the pancreas, small intestine, stomach, esophagus, and other digestive organs; kidney, renal pelvis, and other urinary organs; lung and other respiratory organs; female breast; and miscellaneous organs. The excess risk of a second primary pancreatic NET among women with an FPC at any site was 1.6 per 10,000 person-years and was highest for those with an FPC of the pancreas (2.4 cases per 10,000 person-years).
On average, the second primary pancreatic NET was diagnosed 58 months after diagnosis of the FPC at any site and 59 months after diagnosis of a solid tumor. Time to diagnosis of the pancreatic NET was shortest after FPC of the pancreas (16 months), followed by liver and biliary organs, lung and other respiratory organs (25 months), and stomach, esophagus, and other digestive organs (30 months), whereas it was longest after female breast cancer (69 months). For all sites except the thymus, adrenal gland, and other endocrine organs, women developed second primary pancreatic NET at the same time or somewhat later than did men.
The excess risk of second primary pancreatic NETwas markedly greater in patients who had received radiotherapy for the FPC, and specifically for first primary in the urinary bladder and melanoma and in the stomach, esophagus, and other digestive organs, compared with those who had not received it (Fig. 1) . The same was observed for those who received chemotherapy for cancer in the same sites, and additionally for cancer of the vulva and other female genitals, uterus, cervix, prostate, testes, penis, and other male genitals (Fig. 2) .
DISCUSSION
This study reports that there is an increased risk and excess incidence of second primary pancreatic NETs in patients who were previously diagnosed as having a primary cancer overall and in specific anatomical sites compared with the general population. To our knowledge, this is the first study to have assessed history of primary cancer as a risk factor for a second primary pancreatic NET. Pancreas
As cancer survivorship has increased, the proportion of incident primary cancers that are second or higher-order has also steadily increased from 6% in 1973 13 to 15% in the present data set, which covers 2000 to 2015. We also observed that 8% of people diagnosed as having an FPC developed a second primary tumor. Second primary cancers can be grouped according to predominant etiologic influences as syndromic, cancer treatment-related, and shared etiologic exposures.
14 Syndromic cancers are associated with mutations in major susceptibility genes identified in the familial setting, whose penetrance is influenced by the location of the specific mutation, gene-gene interactions, and gene-environment interactions.
14 In case of pancreatic NET, associated genetic syndromes include MEN1, Von-HippelLindau disease (VHL), and neurofibromatosis type 1 (NF1). 15 The MEN1 syndrome is associated with increased risk of cancers in the endocrine pancreas, anterior pituitary, and parathyroid gland. 3 People with VHL have an increased risk of pancreatic NET along with certain subtypes of kidney cancer (clear cell renal cell carcinoma) and adrenal gland cancer (pheochromocytoma). 16 Although most tumors associated with the NF1 mutation are benign nerve and skin lesions, the risk of breast cancer is 3.5-fold in women with NF1 and 5 times in younger women. 17 In this study, we observed that there was increased risk of second primary pancreatic NET among patients with first primary tumor of the breast (female), kidney, and the thymus, adrenal, and other endocrine organs group, which could be possibly consistent with the above syndromes.
Other than direct genetic mutations, host factors such as impaired immune function and hormonal imbalances may also increase the risk of second primary cancers. Shared etiologic exposures are those that may increase the risk of the first and all subsequent primary tumors in the same individual, including lifestyle or behavioral factors such as tobacco, alcohol, and diet, and environmental factors such as contaminants, pollution, and occupational exposures.
14 In this study, pancreatic NETwas associated with FPC of the lung, stomach, esophageal, kidney, and urinary bladder, all of which share an important etiologic factor, tobacco use. 7, 18 In addition, certain environmental exposures associated with pancreatic tumors (pesticides, cadmium, nickel, metalworking fluids, and mineral oil) also increase the risk of cancer in some of the associated FPC sites, including the kidney, stomach, esophagus, breast, lung, and soft tissues. 19 Because of the nature of the data set, no information on environmental exposures or smoking habits is available.
Radiation and chemotherapy cancer treatments are known to be potentially carcinogenic because of the widespread genetic damage that overwhelms the DNA repair mechanism. 20 Radiotherapy may also interact with genetic susceptibility and tobacco use to increase the risk of a second primary cancer. 21 For most secondary cancer sites, a linear dose-response relationship has been documented for radiotherapy, but the magnitude and shape of this relationship are less clear for pancreatic cancer. 22 The pancreas does not seem to be particularly sensitive to radiation, except when very high doses are used. 21 The total radiation dosage used to treat urinary bladder cancer is typically quite high at 55 to 70 Gy. 23 This may partly explain our observation of increased excess risk in bladder cancer survivors who underwent radiotherapy.
Chemotherapeutic drugs, particularly alkylating agents, topoisomerase II inhibitors, and antimetabolites, have been associated with an increased risk of not only leukemia but also nonhematological tumors. 22, 24 The observed increase in the number of second primary tumors may be partially attributable to greater surveillance in cancer survivors, particularly for certain sites. Surveillance bias may occur if some cancer survivors are followed up more closely or undergo more follow-up diagnostic tests than others, leading to more frequent detection of a second primary cancer. 25 This study has some limitations. Because a very small proportion of FPCs were neuroendocrine, it was difficult to reliably measure excess risk of a second primary pancreatic NET in this subcohort. Cancer therapy data on the use of different chemotherapeutic agents or radiation dosage were not available in the SEER database. However, an important strength of the study is the large sample size, resulting in robust risk estimates for the overall cohort. The use of the most recent SEER 18 registry provided data for 16 years, with the widest possible coverage of the US population available in the SEER databases. Considering the complex mechanisms of carcinogenesis, the risk of a second primary pancreatic NET may be increased depending on not only the site of the FPC and the treatment used, but also interactions with genetic predispositions, environmental exposures, and risk behaviors. More longitudinal studies are needed to confirm the findings from this study and establish clear risk factors for a second primary pancreatic NET.
Cancer survivors should undergo regular follow-up to monitor the pancreas, particularly during the first 5 years after first cancer diagnosis, because that is the average time to occurrence of most second pancreatic NET cases observed in our data. However, the carcinogenic effects of chemotherapy and radiotherapy may be delayed up to and beyond 10 years. 26 Therefore, continued screening is recommended, particularly in survivors with known risk factors such as family history and presence of genetic mutations and in those with increased excess risk (FPCs in the urinary bladder, pancreas, gastrointestinal tract, liver, gallbladder, female breast, thymus, and other endocrine organs). Although environmental and occupational health interventions are mostly at the policy level, individual cancer survivors should be counseled on reducing their exposure to known and suspected carcinogens and endocrine-disrupting chemicals. 27 Lifestyle interventions including smoking cessation, diet, and physical activity may reduce risk of developing a second cancer. 28 
